ArticleESMO open2026
Real-world 5-year outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC.
N Girard et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
5 papers cite it
this papercites it
ArticleESMO open2026
N Girard et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.